Brokerages expect that Sangamo Therapeutics Inc (NASDAQ:SGMO) will post earnings of ($0.30) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Sangamo Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.36) and the highest estimate coming in at ($0.26). Sangamo Therapeutics posted earnings of ($0.18) per share during the same quarter last year, which would indicate a negative year over year growth rate of 66.7%. The firm is expected to issue its next earnings report on Thursday, February 27th.

On average, analysts expect that Sangamo Therapeutics will report full year earnings of ($1.29) per share for the current fiscal year, with EPS estimates ranging from ($1.41) to ($1.17). For the next year, analysts anticipate that the firm will post earnings of ($1.18) per share, with EPS estimates ranging from ($1.75) to $0.10. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Sangamo Therapeutics.

Sangamo Therapeutics (NASDAQ:SGMO) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.10. The company had revenue of $21.96 million for the quarter, compared to analysts’ expectations of $12.16 million. Sangamo Therapeutics had a negative return on equity of 27.32% and a negative net margin of 136.73%. The business’s revenue for the quarter was down 6.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.13) EPS.

SGMO has been the subject of several recent analyst reports. ValuEngine raised Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Zacks Investment Research raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 17th. HC Wainwright initiated coverage on Sangamo Therapeutics in a report on Monday, August 26th. They set a “buy” rating and a $16.00 price objective for the company. Finally, BidaskClub raised Sangamo Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $12.67.

A number of hedge funds have recently made changes to their positions in SGMO. First Manhattan Co. bought a new stake in Sangamo Therapeutics in the second quarter valued at approximately $32,000. Steward Partners Investment Advisory LLC bought a new stake in Sangamo Therapeutics in the second quarter valued at approximately $50,000. Tiverton Asset Management LLC bought a new stake in Sangamo Therapeutics in the second quarter valued at approximately $79,000. Tower Research Capital LLC TRC lifted its position in Sangamo Therapeutics by 1,621.1% in the third quarter. Tower Research Capital LLC TRC now owns 11,170 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 10,521 shares during the last quarter. Finally, McGuire Investment Group LLC bought a new stake in Sangamo Therapeutics in the third quarter valued at approximately $110,000. Hedge funds and other institutional investors own 69.23% of the company’s stock.

Shares of NASDAQ SGMO traded up $0.51 during mid-day trading on Thursday, reaching $9.85. 1,237,000 shares of the company’s stock were exchanged, compared to its average volume of 1,811,887. Sangamo Therapeutics has a 52 week low of $6.26 and a 52 week high of $13.91. The firm has a market capitalization of $1.09 billion, a price-to-earnings ratio of -14.07 and a beta of 2.79. The firm has a 50-day moving average price of $9.03 and a two-hundred day moving average price of $10.37.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.

Recommended Story: Hedge Funds – How They Work For Investors

Get a free copy of the Zacks research report on Sangamo Therapeutics (SGMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.